Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Arvinas (ARVN) stock in Canada | $82.57

Own Arvinas (ARVN) shares in just a few minutes.

Arvinas, Inc
+$7.71 (+8.20%)

Arvinas (ARVN) (ARVN) is a leading biotechnology business based in the US. It opened the day at $81.68 after a previous close of $81.54. During the day the price has varied from a low of $81.17 to a high of $83.67. The latest price was $82.57 (25 minute delay). Arvinas (ARVN) is listed on the NASDAQ and employs 179 staff. All prices are listed in US Dollars.

How to buy Arvinas (ARVN) stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ARVN in this case.
  5. Research Arvinas (ARVN) stocks. The platform should provide the latest information available.
  6. Buy your Arvinas (ARVN) stocks. It's that simple.

How has Coronavirus impacted Arvinas (ARVN)'s stock price?

Since the stock market crash in March caused by coronavirus, Arvinas (ARVN)'s stock price has had significant positive movement.

Its last market close was $72.74, which is 30.62% up on its pre-crash value of $50.47 and 124.16% up on the lowest point reached during the March crash when the stocks fell as low as $32.45.

If you had bought $1,000 worth of Arvinas (ARVN) stocks at the start of February 2020, those stocks would have been worth $703.30 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,456.25.

Arvinas (ARVN) stock price

Use our graph to track the performance of ARVN stocks over time.

Arvinas (ARVN) stocks at a glance

Information last updated 2021-07-09.
Previous close$81.54
Change $1.03
Change % 1.2632%
Volume 240,552
Information last updated 2021-07-22.
52-week range$19.68 - $92.77
50-day moving average $77.6897
200-day moving average $73.4607
Wall St. target price$113.85
Dividend yield N/A (0%)
Earnings per share (TTM) $-7.159

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Arvinas (ARVN) stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Arvinas (ARVN) price performance over time

Historical closes compared with the last close of $82.57

1 month (2021-06-28) 7.54%
3 months (2021-04-28) 18.74%

Arvinas (ARVN) financials

Revenue TTM USD$21.1 million
Gross profit TTM USD$21.8 million
Return on assets TTM -18.55%
Return on equity TTM -33.51%
Profit margin 0%
Book value $12.612
Market capitalisation USD$4.2 billion

TTM: trailing 12 months

How to short and sell Arvinas (ARVN) stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "ARVN.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 3.1 million Arvinas (ARVN) stocks held short by investors – that's known as Arvinas (ARVN)'s "short interest". This figure is 5.7% up from 2.9 million last month.

There are a few different ways that this level of interest in shorting Arvinas (ARVN) stocks can be evaluated.

Arvinas (ARVN)'s "short interest ratio" (SIR)

Arvinas (ARVN)'s "short interest ratio" (SIR) is the quantity of Arvinas (ARVN) stocks currently shorted divided by the average quantity of Arvinas (ARVN) stocks traded daily (recently around 588835.19230769). Arvinas (ARVN)'s SIR currently stands at 5.2. In other words for every 100,000 Arvinas (ARVN) stocks traded daily on the market, roughly 5200 stocks are currently held short.

However Arvinas (ARVN)'s short interest can also be evaluated against the total number of Arvinas (ARVN) stocks, or, against the total number of tradable Arvinas (ARVN) stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arvinas (ARVN)'s short interest could be expressed as 0.06% of the outstanding stocks (for every 100,000 Arvinas (ARVN) stocks in existence, roughly 60 stocks are currently held short) or 0.0728% of the tradable stocks (for every 100,000 tradable Arvinas (ARVN) stocks, roughly 73 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Arvinas (ARVN).

Find out more about how you can short Arvinas (ARVN) stock.

Arvinas (ARVN) stock dividends

We're not expecting Arvinas (ARVN) to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Arvinas (ARVN) stock price volatility

Over the last 12 months, Arvinas (ARVN)'s stocks have ranged in value from as little as $19.68 up to $92.77. A popular way to gauge a stock's volatility is its "beta".

ARVN.US volatility(beta: 2.01)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arvinas (ARVN)'s is 2.006. This would suggest that Arvinas (ARVN)'s stocks are significantly more volatile than the average for this exchange and represent a higher risk.

Arvinas (ARVN) overview

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site